P2X receptor-mediated ATP purinergic signaling in health and disease

Cell Health and Cytoskeleton

Volumn 4, Issue , 2012, Pages 83-101

  Jiang, Lin Hua ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Chronic pain; Extracellular ATP; Inflammatory diseases; Ion channel; Large pore; Signaling complex

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; 5 [[(3 PHENOXYBENZYL)(1,2,3,4 TETRAHYDRO 1 NAPHTHYL)AMINO]CARBONYL]TRIMELLITIC ACID; A 740003; ADENOSINE TRIPHOSPHATE; BBG; CARBENOXOLONE; DIINOSINE PENTAPHOSPHATE; NF 023; NF 110; NF 157; NF 279; NF 449; PURINERGIC P2X RECEPTOR; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X7 RECEPTOR; RO 0437626; RO 1; SPINORPIN; SURAMIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHANNEL GATING; CHRONIC PAIN; DRUG ANTAGONISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLIA CELL; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATORY DISEASE; LUNG FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SPLICING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE CONTRACTION;

EID: 84874788578     PISSN: None     EISSN: 11791330     Source Type: Journal    
DOI: 10.2147/CHC.S27196     Document Type: Review

References (225)

1. Burnstock G. Discovery of Purinergic Signalling, the Initial Resistance and Current Explosion of Interest. Br J Pharmacol. 2012;2:238-255.
2. Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2009;32(1):19-29.
3. Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol. 2009;71:333-359.
4. Burnstock G, Fredholm BB, North RA, Verkhratsky A. The birth and postnatal development of purinergic signalling. Acta Physiol (Oxf). 2010;199(2):93-147.
5. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006;442(7102):527-532.
6. North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82(4):1013-1067.
7. Adinolfi E, Cirillo M, Woltersdorf R, etal. Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J. 2010;24(9):3393-3404.
8. Nicke A, Kuan YH, Masin M, etal. A functional P2X7splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem. 2009;284(38):25813-25822.
9. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S. Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun. 2005;332(1):17-27.
10. Feng YH, Li X, Wang L, Zhou L, Gorodeski GI. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem. 2006;281(25):17228-17237.
11. Masin M, Young C, Lim K, etal. Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. Br J Pharmacol. 2012;165(4):978-993.
12. Bo X, Jiang LH, Wilson HL, etal. Pharmacological and biophysical properties of the human P2X5 receptor. Mol Pharmacol. 2003;63(6):1407-1416.
13. Barrera NP, Ormond SJ, Henderson RM, Murrell-Lagnado RD, Edwardson JM. Atomic force microscopy imaging demonstrates that P2X2 receptors are trimers but that P2X6 receptor subunits do not oligomerize. J Biol Chem. 2005;280(11):10759-10765.
14. Ormond SJ, Barrera NP, Qureshi OS, Henderson RM, Edwardson JM, Murrell-Lagnado RD. An uncharged region within the N terminus of the P2X6 receptor inhibits its assembly and exit from the endoplasmic reticulum. Mol Pharmacol. 2006;69(5):1692-1700.
15. Compan V, Ulmann L, Stelmashenko O, Chemin J, Chaumont S, Rassendren F. P2X2 and P2X5subunits define a new heteromeric receptor with P2X7-like properties. J Neurosci. 2012;32(12):4284-4296.
16. Nicke A, Baumert HG, Rettinger J, etal. P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J. 1998;17(11):3016-3028.
17. Jiang LH, Kim M, Spelta V, Bo X, Surprenant A, North RA. Subunit arrangement in P2X receptors. J Neurosci. 2003;23(26):8903-8910.
18. Wilkinson WJ, Jiang LH, Surprenant A, North RA. Role of ectodomain lysines in the subunits of the heteromeric P2X2/3 receptor. Mol Pharmacol. 2006;70(4):1159-1163.
19. Marquez-Klaka B, Rettinger J, Bhargava Y, Eisele T, Nicke A. Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor. J Neurosci. 2007;27(6):1456-1466.
20. Marquez-Klaka B, Rettinger J, Nicke A. Inter-subunit disulfide cross-linking in homomeric and heteromeric P2X receptors. Eur Biophys J. 2009;38(3):329-338.
21. Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature. 2009;460(7255):592-598.
22. Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012;485(7397):207-212.
23. Browne LE, Jiang LH, North RA. New structure enlivens interest in P2X receptors. Trends Pharmacol Sci. 2010;31(5):229-237.
24. Evans RJ. Structural interpretation of P2X receptor mutagenesis studies on drug action. Br J Pharmacol. 2010;161(5):961-971.
25. Roger S, Mei ZZ, Baldwin JM, etal. Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res. 2010;44(6):347-355.
26. Bradley HJ, Baldwin JM, Goli GR, etal. Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem. 2011;286(10):8176-8187.
27. Gonzales EB, Kawate T, Gouaux E. Pore architecture and ion sites in acid-sensing ion channels and P2X receptors. Nature. 2009;460(7255):599-604.
28. Egan TM, Khakh BS. Contribution of calcium ions to P2X channel responses. J Neurosci. 2004;24(13):3413-3420.
29. Wang X, Kim SU, van Breemen C, McLarnon JG. Activation of purinergic P2X receptors inhibits P2Y-mediated Ca2+ influx in human microglia. Cell Calcium. 2000;27(4):205-212.
30. Baxter AW, Choi SJ, Sim JA, North RA. Role of P2X4 receptors in synaptic strengthening in mouse CA1 hippocampal neurons. Eur J Neurosci. 2011;34(2):213-220.
31. Khakh BS, Gittermann D, Cockayne DA, Jones A. ATP modulation of excitatory synapses onto interneurons. J Neurosci. 2003;23(19):7426-7437.
32. Zhang X, Chen Y, Wang C, Huang LY. Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia. Proc Natl Acad Sci U S A. 2007;104(23):9864-9869.
33. Lalo U, Andrew J, Palygin O, Pankratov Y. Ca2+-dependent modulation of GABAA and NMDA receptors by extracellular ATP: implication for function of tripartite synapse. Biochem Soc Trans. 2009;37(Pt 6):1407-1411.
34. Pankratov Y, Lalo U, Krishtal OA, Verkhratsky A. P2X receptors and synaptic plasticity. Neuroscience. 2009;158(1):137-148.
35. Mulryan K, Gitterman DP, Lewis CJ, etal. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature. 2000;403(6765):86-89.
36. Povstyan OV, Harhun MI, Gordienko DV. Ca2+ entry following P2X receptor activation induces IP3 receptor-mediated Ca2+ release in myocytes from small renal arteries. Br J Pharmacol. 2011;162(7):1618-1638.
37. Amobi NI, Guillebaud J, Smith IC. Perspective on the role of P2X-purinoceptor activation in human vas deferens contractility. Exp Physiol. 2012;97(5):583-602.
38. Yamamoto K, Sokabe T, Matsumoto T, etal. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med. 2006;12(1):133-137.
39. Adinolfi E, Callegari MG, Cirillo M, etal. Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem. 2009;284(15):10120-10128.
40. Hill LM, Gavala ML, Lenertz LY, Bertics PJ. Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol. 2010;185(5):3028-3034.
41. Chen Y, Zhang X, Wang C, Li G, Gu Y, Huang LY. Activation of P2X7 receptors in glial satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons. Proc Natl Acad Sci U S A. 2008;105(43):16773-16778.
42. Labasi JM, Petrushova N, Donovan C, etal. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol. 2002;168(12):6436-6445.
43. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272(5262):735-738.
44. Khakh BS, Bao XR, Labarca C, Lester HA. Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds. Nat Neurosci. 1999;2(4):322-330.
45. Virginio C, MacKenzie A, Rassendren FA, North RA, Surprenant A. Pore dilation of neuronal P2X receptor channels. Nat Neurosci. 1999;2(4):315-321.
46. Eickhorst AN, Berson A, Cockayne D, Lester HA, Khakh BS. Control of P2X(2) channel permeability by the cytosolic domain. J Gen Physiol. 2002;120(2):119-131.
47. Pelegrin P, Surprenant A. Pannexin-1mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006;25(21):5071-5082.
48. Sorge RE, Trang T, Dorfman R, etal. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012;18(4):595-599.
49. Scemes E, Spray DC. Extracellular K(+) and Astrocyte Signaling via Connexin and Pannexin Channels. Neurochem Res. 2012. [Epub ahead of print].
50. Qu Y, Misaghi S, Newton K, etal. Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol. 2011;186(11):6553-6561.
51. Xu XJ, Boumechache M, Robinson LE, etal. Splice-variants of the P2X7 receptor reveal differential agonist-dependence and functional coupling with pannexin-1. J Cell Sci. 2012. [Epub ahead of print].
52. Chaumont S, Khakh BS. Patch-clamp coordinated spectroscopy shows P2X2 receptor permeability dynamics require cytosolic domain rearrangements but not Panx-1 channels. Proc Natl Acad Sci U S A. 2008;105(33):12063-12068.
53. Bernier LP, Ase AR, Boue-Grabot E, Seguela P. P2X4 receptor channels form large noncytolytic pores in resting and activated microglia. Glia. 2012;60(5):728-737.
54. Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci. 2009;29(12):3781-3791.
55. Fujiwara Y, Keceli B, Nakajo K, Kubo Y. Voltage-and [ATP]-dependent gating of the P2X(2) ATP receptor channel. J Gen Physiol. 2009;133(1):93-109.
56. Le Stunff H, Auger R, Kanellopoulos J, Raymond MN. The Pro-451 to Leu polymorphism within the C-terminal tail of P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes. J Biol Chem. 2004;279(17):16918-16926.
57. Bianco F, Ceruti S, Colombo A, etal. A role for P2X7in microglial proliferation. J Neurochem. 2006;99(3):745-758.
58. Virginio C, MacKenzie A, North RA, Surprenant A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J Physiol. 1999;519 Pt 2:335-346.
59. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity. 2001;15(5):825-835.
60. Mackenzie AB, Young MT, Adinolfi E, Surprenant A. Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. J Biol Chem. 2005;280(40):33968-33976.
61. Qu Y, Franchi L, Nunez G, Dubyak GR. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol. 2007;179(3):1913-1925.
62. Fang KM, Yang CS, Sun SH, Tzeng SF. Microglial phagocytosis attenuated by short-term exposure to exogenous ATP through P2X receptor action. J Neurochem. 2009;111(5):1225-1237.
63. Gulbransen BD, Bashashati M, Hirota SA, etal. Activation of neuronal P2X7 receptor-pannexin-1mediates death of enteric neurons during colitis. Nat Med. 2012;18(4):600-604.
64. Kim M, Jiang LH, Wilson HL, North RA, Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 2001;20(22):6347-6358.
65. Wilson HL, Wilson SA, Surprenant A, North RA. Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. J Biol Chem. 2002;277(37):34017-34023.
66. Roger S, Pelegrin P, Surprenant A. Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. J Neurosci. 2008;28(25):6393-6401.
67. Michel AD, Fonfria E. Agonist potency at P2X7 receptors is modulated by structurally diverse lipids. Br J Pharmacol. 2007;152(4):523-537.
68. Vial C, Evans RJ. Disruption of lipid rafts inhibits P2X1 receptor-mediated currents and arterial vasoconstriction. J Biol Chem. 2005;280(35):30705-30711.
69. Allsopp RC, Lalo U, Evans RJ. Lipid raft association and cholesterol sensitivity of P2X1-4 receptors for ATP: chimeras and point mutants identify intracellular amino-terminal residues involved in lipid regulation of P2X1 receptors. J Biol Chem. 2010;285(43):32770-32777.
70. Lalo U, Roberts JA, Evans RJ. Identification of human P2X1 receptor-interacting proteins reveals a role of the cytoskeleton in receptor regulation. J Biol Chem. 2011;286(35):30591-30599.
71. Chaumont S, Compan V, Toulme E, etal. Regulation of P2X2 receptors by the neuronal calcium sensor VILIP1. Sci Signal. 2008;1(41):ra8.
72. Xia R, Mei ZZ, Milligan C, Jiang LH. Inhibitory interaction between P2X4 and GABA(C) rho1 receptors. Biochem Biophys Res Commun. 2008;375(1):38-43.
73. Khakh BS, Zhou X, Sydes J, Galligan JJ, Lester HA. State-dependent cross-inhibition between transmitter-gated cation channels. Nature. 2000;406(6794):405-410.
74. Boue-Grabot E, Emerit MB, Toulme E, Seguela P, Garret M. Cross-talk and co-trafficking between rho1/GABA receptors and ATP-gated channels. J Biol Chem. 2004;279(8):6967-6975.
75. Boue-Grabot E, Toulme E, Emerit MB, Garret M. Subunit-specific coupling between gamma-aminobutyric acid type A and P2X2 receptor channels. J Biol Chem. 2004;279(50):52517-52525.
76. Toulme E, Blais D, Leger C, etal. An intracellular motif of P2X(3) receptors is required for functional cross-talk with GABA(A) receptors in nociceptive DRG neurons. J Neurochem. 2007;102(4):1357-1368.
77. Jo YH, Donier E, Martinez A, Garret M, Toulme E, Boue-Grabot E. Cross-talk between P2X4 and gamma-aminobutyric acid, type A receptors determines synaptic efficacy at a central synapse. J Biol Chem. 2011;286(22):19993-20004.
78. Jo YH, Boue-Grabot E. Interplay between ionotropic receptors modulates inhibitory synaptic strength. Commun Integr Biol. 2011;4(6):706-709.
79. Bernier LP, Ase AR, Chevallier S, etal. Phosphoinositides regulate P2X4 ATP-gated channels through direct interactions. J Neurosci. 2008;28(48):12938-12945.
80. Evans RJ, Derkach V, Surprenant A. ATP mediates fast synaptic transmission in mammalian neurons. Nature. 1992;357(6378):503-505.
81. Edwards FA, Gibb AJ, Colquhoun D. ATP receptor-mediated synaptic currents in the central nervous system. Nature. 1992;359(6391):144-147.
82. Cockayne DA, Hamilton SG, Zhu QM, etal. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807):1011-1015.
83. Cockayne DA, Dunn PM, Zhong Y, etal. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol. 2005;567(Pt 2):621-639.
84. Solle M, Labasi J, Perregaux DG, etal. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem. 2001;276(1):125-132.
85. Finger TE, Danilova V, Barrows J, etal. ATP signaling is crucial for communication from taste buds to gustatory nerves. Science. 2005;310(5753):1495-1499.
86. Lopez-Castejon G, Theaker J, Pelegrin P, Clifton AD, Braddock M, Surprenant A. P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol. 2010;185(4):2611-2619.
87. Seman M, Adriouch S, Scheuplein F, etal. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity. 2003;19(4):571-582.
88. Hong S, Schwarz N, Brass A, etal. Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells. J Immunol. 2009;183(1):578-592.
89. Chessell IP, Hatcher JP, Bountra C, etal. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114(3):386-396.
90. Taylor SR, Gonzalez-Begne M, Sojka DK, etal. Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J Leukoc Biol. 2009;85(6):978-986.
91. Sanchez-Nogueiro J, Marin-Garcia P, Miras-Portugal MT. Characterization of a functional P2X(7)-like receptor in cerebellar granule neurons from P2X(7) knockout mice. FEBS Lett. 2005;579(17):3783-3788.
92. Anderson CM, Nedergaard M. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends Neurosci. 2006;29(5):257-262.
93. Bleehen T, Keele CA. Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain. 1977;3(4):367-377.
94. Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X purinoceptor expressed by a subset of sensory neurons. Nature. 1995;377(6548):428-431.
95. Lewis C, Neidhart S, Holy C, North RA, Buell G, Surprenant A. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature. 1995;377(6548):432-435.
96. Souslova V, Cesare P, Ding Y, etal. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature. 2000;407(6807):1015-1017.
97. Sim JA, Chaumont S, Jo J, etal. Altered hippocampal synaptic potentiation in P2X4 knock-out mice. J Neurosci. 2006;26(35):9006-9009.
98. Tsuda M, Shigemoto-Mogami Y, Koizumi S, etal. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424(6950):778-783.
99. Ulmann L, Hatcher JP, Hughes JP, etal. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci. 2008;28(44):11263-11268.
100. Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, Inoue K. Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays. Mol Pain. 2009;5:28.
101. Ulmann L, Hirbec H, Rassendren F. P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain. EMBO J. 2010;29(14):2290-2300.
102. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med. 2002;8(8):390-396.
103. Brough D, Le Feuvre RA, Iwakura Y, Rothwell NJ. Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci. 2002;19(2):272-280.
104. Le Feuvre RA, Brough D, Iwakura Y, Takeda K, Rothwell NJ. Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J Biol Chem. 2002;277(5):3210-3218.
105. Riteau N, Gasse P, Fauconnier L, etal. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med. 2010;182(6):774-783.
106. Chong JH, Zheng GG, Ma YY, etal. The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice. J Biol Chem. 2010;285(46):36179-36187.
107. Adinolfi E, Melchiorri L, Falzoni S, etal. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99(2):706-708.
108. Wiley JS, Dao-Ung LP, Gu BJ, etal. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet. 2002;359(9312):1114-1119.
109. Greig AV, Linge C, Healy V, etal. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431cells. J Invest Dermatol. 2003;121(2):315-327.
110. Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski GI. P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol. 2004;287(5):C1349-C1358.
111. Coutinho-Silva R, Stahl L, Cheung KK, etal. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G1024-G1035.
112. Dardano A, Falzoni S, Caraccio N, etal. 1513A. >C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab. 2009;94(2):695-698.
113. Gu LQ, Li FY, Zhao L, etal. Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine. 2010;38(2):276-282.
114. Adinolfi E, Raffaghello L, Giuliani AL, etal. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012;72(12):2957-2969.
115. Thunberg U, Tobin G, Johnson A, etal. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet. 2002;360(9349):1935-1939.
116. Jelassi B, Chantome A, Alcaraz-Perez F, etal. P2X(7) receptor activation enhances SK3 channels-and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011;30(18):2108-2122.
117. Soto F, Lambrecht G, Nickel P, Stuhmer W, Busch AE. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology. 1999;38(1):141-149.
118. Klapperstuck M, Buttner C, Nickel P, Schmalzing G, Lambrecht G, Markwardt F. Antagonism by the suramin analogue NF279 on human P2X(1) and P2X(7) receptors. Eur J Pharmacol. 2000;387(3):245-252.
119. Rettinger J, Schmalzing G, Damer S, Muller G, Nickel P, Lambrecht G. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. Neuropharmacology. 2000;39(11):2044-2053.
120. Braun K, Rettinger J, Ganso M, etal. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(3):285-290.
121. Kassack MU, Braun K, Ganso M, etal. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004;39(4):345-357.
122. Rettinger J, Braun K, Hochmann H, etal. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology. 2005;48(3):461-468.
123. King BF, Liu M, Pintor J, Gualix J, Miras-Portugal MT, Burnstock G. Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors. Br J Pharmacol. 1999;128(5):981-988.
124. Dunn PM, Liu M, Zhong Y, King BF, Burnstock G. Diinosine pentaphosphate: an antagonist which discriminates between recombinant P2X(3) and P2X(2/3) receptors and between two P2X receptors in rat sensory neurones. Br J Pharmacol. 2000;130(6):1378-1384.
125. Ford KK, Matchett M, Krause JE, Yu W. The P2X3 antagonist P1, P5-di[inosine-5′] pentaphosphate binds to the desensitized state of the receptor in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 2005;315(1):405-413.
126. Virginio C, Robertson G, Surprenant A, North RA. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998;53(6):969-973.
127. Burgard EC, Niforatos W, van Biesen T, etal. Competitive antagonism of recombinant P2X(2/3) receptors by 2′, 3′-O-(2,4,6-trinitrophenyl) adenosine 5′-triphosphate (TNP-ATP). Mol Pharmacol. 2000;58(6):1502-1510.
128. Neelands TR, Burgard EC, Uchic ME, etal. 2′, 3′-O-(2,4,6, trinitrophenyl)-ATP and A-317491 are competitive antagonists at a slowly desensitizing chimeric human P2X3 receptor. Br J Pharmacol. 2003;140(1):202-210.
129. Surprenant A, Schneider DA, Wilson HL, Galligan JJ, North RA. Functional properties of heteromeric P2X(1/5) receptors expressed in HEK cells and excitatory junction potentials in guinea-pig submucosal arterioles. J Auton Nerv Syst. 2000;81(1-3):249-263.
130. Gargett CE, Wiley JS. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol. 1997;120(8):1483-1490.
131. Humphreys BD, Virginio C, Surprenant A, Rice J, Dubyak GR. Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol Pharmacol. 1998;54(1):22-32.
132. Baraldi PG, del Carmen Nunez M, Morelli A, Falzoni S, Di Virgilio F, Romagnoli R. Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. J Med Chem. 2003;46(8):1318-1329.
133. Lee GE, Joshi BV, Chen W, etal. Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. Bioorg Med Chem Lett. 2008;18(2):571-575.
134. Romagnoli R, Baraldi PG, Carrion MD, etal. From tyrosine to glycine: synthesis and biological activity of potent antagonists of the purinergic P2X7 receptor. J Med Chem. 2007;50(15):3706-3715.
135. Jiang LH, Mackenzie AB, North RA, Surprenant A. Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol. 2000;58(1):82-88.
136. Jaime-Figueroa S, Greenhouse R, Padilla F, Dillon MP, Gever JR, Ford AP. Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist. Bioorg Med Chem Lett. 2005;15(13):3292-3295.
137. Ford AP, Gever JR, Nunn PA, etal. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol. 2006;147 Suppl 2:S132-S143.
138. Jarvis MF, Burgard EC, McGaraughty S, etal. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A. 2002;99(26):17179-17184.
139. Carter DS, Alam M, Cai H, etal. Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009;19(6):1628-1631.
140. Jahangir A, Alam M, Carter DS, etal. Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009;19(6):1632-1635.
141. Kaan TK, Yip PK, Patel S, etal. Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain. 2010;133(9):2549-2564.
142. Brotherton-Pleiss CE, Dillon MP, Ford AP, etal. Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist. Bioorg Med Chem Lett. 2010;20(3):1031-1036.
143. Nelson DW, Gregg RJ, Kort ME, etal. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem. 2006;49(12):3659-3666.
144. Carroll WA, Kalvin DM, Perez Medrano A, etal. Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists. Bioorg Med Chem Lett. 2007;17(14):4044-4048.
145. Florjancic AS, Peddi S, Perez-Medrano A, etal. Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists. Bioorg Med Chem Lett. 2008;18(6):2089-2092.
146. McGaraughty S, Chu KL, Namovic MT, etal. P2X7-related modulation of pathological nociception in rats. Neuroscience. 2007;146(4):1817-1828.
147. Honore P, Donnelly-Roberts D, Namovic M, etal. The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res. 2009;204(1):77-81.
148. Perez-Medrano A, Donnelly-Roberts DL, Honore P, etal. Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain. J Med Chem. 2009;52(10):3366-3376.
149. Morytko MJ, Betschmann P, Woller K, etal. Synthesis and in vitro activity of N′-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists. Bioorg Med Chem Lett. 2008;18(6):2093-2096.
150. Honore P, Donnelly-Roberts D, Namovic MT, etal. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther. 2006;319(3):1376-1385.
151. Donnelly-Roberts DL, Namovic MT, Surber B, etal. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology. 2009;56(1):223-229.
152. Alcaraz L, Baxter A, Bent J, etal. Novel P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003;13(22):4043-4046.
153. Stokes L, Jiang LH, Alcaraz L, etal. Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br J Pharmacol. 2006;149(7):880-887.
154. Baxter A, Bent J, Bowers K, etal. Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003;13(22):4047-4050.
155. Furber M, Alcaraz L, Bent JE, etal. Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors. J Med Chem. 2007;50(24):5882-5885.
156. Michel AD, Chambers LJ, Walter DS. Negative and positive allosteric modulators of the P2X(7) receptor. Br J Pharmacol. 2008;153(4):737-750.
157. Duplantier AJ, Dombroski MA, Subramanyam C, etal. Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Bioorg Med Chem Lett. 2011;21(12):3708-3711.
158. Gum RJ, Wakefield B, Jarvis MF. P2X receptor antagonists for pain management: examination of binding and physicochemical properties. Purinergic Signal. 2012;8(Suppl 1):41-56.
159. McGaraughty S, Wismer CT, Zhu CZ, etal. Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br J Pharmacol. 2003;140(8):1381-1388.
160. Gever JR, Soto R, Henningsen RA, etal. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010;160(6):1387-1398.
161. Weigand LA, Ford AP, Undem BJ. Role for ATP in bronchoconstriction-induced activation of guinea pig vagal intrapulmonary C-fibers. J Physiol. 2012;S90(Pt16):4109-4120.
162. Kaan TK, Yip PK, Grist J, etal. Endogenous purinergic control of bladder activity via presynaptic P2X3 and P2X2/3 receptors in the spinal cord. J Neurosci. 2010;30(12):4503-4507.
163. Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci. 2010;30(2):573-582.
164. Peng W, Cotrina ML, Han X, etal. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci U S A. 2009;106(30):12489-12493.
165. Guile SD, Alcaraz L, Birkinshaw TN, etal. Antagonists of the P2X(7) receptor. From lead identification to drug development. J Med Chem.2009;52(10):3123-3141.
166. Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2011. [Epub ahead of print].
167. Stock TC, Bloom BJ, Wei N, etal. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39(4):720-727.
168. Marcillo A, Frydel B, Bramlett HM, Dietrich WD. A reassessment of P2X7 receptor inhibition as a neuroprotective strategy in rat models of contusion injury. Exp Neurol. 2012;233(2):687-692.
169. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. J Clin Invest. 2003;112(12):1895-1905.
170. Hechler B, Lenain N, Marchese P, etal. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med. 2003;198(4):661-667.
171. Lecut C, Frederix K, Johnson DM, etal. P2X1 ion channels promote neutrophil chemotaxis through Rho kinase activation. J Immunol. 2009;183(4):2801-2809.
172. Ren J, Bian X, DeVries M, etal. P2X2subunits contribute to fast synaptic excitation in myenteric neurons of the mouse small intestine. J Physiol. 2003;552(Pt 3):809-821.
173. Ryten M, Koshi R, Knight GE, etal. Abnormalities in neuromuscular junction structure and skeletal muscle function in mice lacking the P2X2 nucleotide receptor. Neuroscience. 2007;148(3):700-711.
174. Huang YA, Stone LM, Pereira E, etal. Knocking out P2X receptors reduces transmitter secretion in taste buds. J Neurosci. 2011;31(38):13654-13661.
175. Custer EE, Knott TK, Cuadra AE, Ortiz-Miranda S, Lemos JR. P2X purinergic receptor knockout mice reveal endogenous ATP modulation of both vasopressin and oxytocin release from the intact neurohypophysis. J Neuroendocrinol. 2012;24(4):674-680.
176. Navarro B, Miki K, Clapham DE. ATP-activated P2X2 current in mouse spermatozoa. Proc Natl Acad Sci U S A. 2011;108(34):14342-14347.
177. Vlaskovska M, Kasakov L, Rong W, etal. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001;21(15):5670-5677.
178. Bian X, Ren J, DeVries M, etal. Peristalsis is impaired in the small intestine of mice lacking the P2X3subunit. J Physiol. 2003;551(Pt 1):309-322.
179. Rong W, Gourine AV, Cockayne DA, etal. Pivotal role of nucleotide P2X2 receptor subunit of the ATP-gated ion channel mediating ventilatory responses to hypoxia. J Neurosci. 2003;23(36):11315-11321.
180. Shimizu I, Iida T, Guan Y, etal. Enhanced thermal avoidance in mice lacking the ATP receptor P2X3. Pain. 2005;116(1-2):96-108.
181. Wang Y, Mackes J, Chan S, etal. Impaired long-term depression in P2X3 deficient mice is not associated with a spatial learning deficit. J Neurochem. 2006;99(5):1425-1434.
182. Ke HZ, Qi H, Weidema AF, etal. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol. 2003;17(7):1356-1367.
183. Li J, Liu D, Ke HZ, Duncan RL, Turner CH. The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem. 2005;280(52):42952-42959.
184. Korcok J, Raimundo LN, Ke HZ, Sims SM, Dixon SJ. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res. 2004;19(4):642-651.
185. Panupinthu N, Zhao L, Possmayer F, Ke HZ, Sims SM, Dixon SJ. P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. J Biol Chem. 2007;282(5):3403-3412.
186. Kawamura H, Aswad F, Minagawa M, etal. P2X7 receptor-dependent and-independent T cell death is induced by nicotinamide adenine dinucleotide. J Immunol. 2005;174(4):1971-1979.
187. Suadicani SO, Brosnan CF, Scemes E. P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling. J Neurosci. 2006;26(5):1378-1385.
188. Kawamura H, Aswad F, Minagawa M, Govindarajan S, Dennert G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J Immunol. 2006;176(4):2152-2160.
189. Nakamoto T, Brown DA, Catalan MA, Gonzalez-Begne M, Romanenko VG, Melvin JE. Purinergic P2X7 receptors mediate ATP-induced saliva secretion by the mouse submandibular gland. J Biol Chem. 2009;284(8):4815-4822.
190. Novak I, Jans IM, Wohlfahrt L. Effect of P2X(7) receptor knockout on exocrine secretion of pancreas, salivary glands and lacrimal glands. J Physiol. 2010;588(Pt 18):3615-3627.
191. Inscho EW, Cook AK, Clarke A, Zhang S, Guan Z. P2X1 receptor-mediated vasoconstriction of afferent arterioles in angiotensin II-infused hypertensive rats fed a high-salt diet. Hypertension. 2011;57(4):780-787.
192. Ito K, Iwami A, Katsura H, Ikeda M. Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4-6):483-490.
193. Fairbairn IP, Stober CB, Kumararatne DS, Lammas DA. ATP-mediated killing of intracellular mycobacteria by macrophages is a P2X(7)-dependent process inducing bacterial death by phagosome-lysosome fusion. J Immunol. 2001;167(6):3300-3307.
194. Shemon AN, Sluyter R, Fernando SL, etal. A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem. 2006;281(4):2079-2086.
195. Fernando SL, Saunders BM, Sluyter R, etal. A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med. 2007;175(4):360-366.
196. Goncalves RG, Gabrich L, Rosario A Jr, etal. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int. 2006;70(9):1599-1606.
197. Diaz-Hernandez M, Diez-Zaera M, Sanchez-Nogueiro J, etal. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J. 2009;23(6):1893-1906.
198. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R. P2X7mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem. 2003;278(15):13309-13317.
199. McLarnon JG, Ryu JK, Walker DG, Choi HB. Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol. 2006;65(11):1090-1097.
200. Skaper SD, Facci L, Culbert AA, etal. P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro. Glia. 2006;54(3):234-242.
201. Sanz JM, Chiozzi P, Ferrari D, etal. Activation of microglia by amyloid {beta} requires P2X7 receptor expression. J Immunol. 2009;182(7):4378-4385.
202. Lee HG, Won SM, Gwag BJ, Lee YB. Microglial P2X(7) receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9mouse model of Alzheimer's disease. Exp Mol Med. 2011;43(1):7-14.
203. Taylor SR, Turner CM, Elliott JI, etal. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol. 2009;20(6):1275-1281.
204. Wilhelm K, Ganesan J, Muller T, etal. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16(12):1434-1438.
205. Zhou D, Chen ML, Zhang YQ, Zhao ZQ. Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats. J Neurosci. 2010;30(23):8042-8047.
206. Gandelman M, Peluffo H, Beckman JS, Cassina P, Barbeito L. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:33.
207. Kim JE, Kang TC. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J Clin Invest. 2011;121(5):2037-2047.
208. Keating C, Pelegrin P, Martinez CM, Grundy D. P2X7 receptor-dependent intestinal afferent hypersensitivity in a mouse model of postinfectious irritable bowel syndrome. J Immunol. 2011;187(3):1467-1474.
209. Martins JP, Silva RB, Coutinho-Silva R, etal. The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. Br J Pharmacol. 2012;165(1):183-196.
210. Barden N, Harvey M, Gagne B, etal. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(4):374-382.
211. Lucae S, Salyakina D, Barden N, etal. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet. 2006;15(16):2438-2445.
212. Hejjas K, Szekely A, Domotor E, etal. Association between depression and the Gln460Arg polymorphism of P2RX7gene: a dimensional approach. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(2):295-299.
213. McQuillin A, Bass NJ, Choudhury K, etal. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar-and unipolar-affective disorders. Mol Psychiatry. 2009;14(6):614-620.
214. Gidlof O, Smith JG, Melander O, etal. A common missense variant in the ATP receptor P2X7 is associated with reduced risk of cardiovascular events. PLoS One. 2012;7(5):e37491.
215. Evans RJ, Lewis C, Buell G, Valera S, North RA, Surprenant A. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). Mol Pharmacol. 1995;48(2):178-183.
216. Ullmann H, Meis S, Hongwiset D, etal. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005;48(22):7040-7048.
217. North RA, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol. 2000;40:563-580.
218. Fonfria E, Clay WC, Levy DS, etal. Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue. Br J Pharmacol. 2008;153(3):544-556.
219. Hulsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F. NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol. 2003;470(1-2):1-7.
220. Hausmann R, Rettinger J, Gerevich Z, etal. The suramin analog 4,4′,4″,4″′-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol. 2006;69(6):2058-2067.
221. Jung KY, Moon HD, Lee GE, Lim HH, Park CS, Kim YC. Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007;50(18):4543-4547.
222. Donnelly-Roberts D, McGaraughty S, Shieh CC, Honore P, Jarvis MF. Painful purinergic receptors. J Pharmacol Exp Ther. 2008;324(2):409-415.
223. Roman S, Cusdin FS, Fonfria E, etal. Cloning and pharmacological characterization of the dog P2X7 receptor. Br J Pharmacol. 2009;158(6):1513-1526.
224. Bradley HJ, Browne LE, Yang W, Jiang LH. Pharmacological properties of the rhesus macaque monkey P2X7 receptor. Br J Pharmacol. 2011;164(2b):743-754.
225. Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, Chessell IP. Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol. 2007;151(1):103-114.